ReviewCurrent neurology and neuroscience reports2017
Neurological Complications of Therapeutic Monoclonal Antibodies: Trends from Oncology to Rheumatology.
Review in Current neurology and neuroscience reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- The Adverse Effects Profile of Teprotumumab.The Journal of clinical endocrinology and metabolism · 2023Review
- Immunopathology of Tumefactive Demyelinating Lesions-From Idiopathic to Drug-Related Cases.Frontiers in neurology · 2022Review
- Rapidly progressive cognitive decline associated with teprotumumab in thyroid eye disease.BMJ case reports · 2021Article
- Infliximab-induced seizures in a patient with Crohn's disease: a case report.BMC gastroenterology · 2021Article
- Dapsone-induced DRESS after infliximab-induced vasculitis: a case of cerebral infarction in the context of multiple drug reactions.BMJ case reports · 2020Article
- Pathological findings in central nervous system demyelination associated with infliximab.Multiple sclerosis (Houndmills, Basingstoke, England) · 2020Article
- Encephalomyeloneuritis and arthritis after treatment with immune checkpoint inhibitors.Neurology(R) neuroimmunology & neuroinflammation · 2020Article
- Critical Care Management of Toxicities Associated With Targeted Agents and Immunotherapies for Cancer.Critical care medicine · 2020Review
- Ramsay-Hunt syndrome and subsequent sensory neuropathy as potential immune-related adverse events of nivolumab: a case report.BMC cancer · 2019Article
- Safety of Infliximab for the Eye Under Human T-Cell Leukemia Virus Type 1 Infectious ConditionsFrontiers in microbiology · 2019Article
- Neurobehçet, multiple sclerosis or overlap syndrome? A case report.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThis review is to describe the scope of neurological complications associated with monoclonal antibody-based therapies, applied across medical specialties, to demonstrate the common and rare neurological syndromes that may be encountered in clinical practice according to the therapeutic agent being receive, and to explain appropriate work-up, diagnosis, and management of drug complications, as supported by the literature. RECENT
findingsThe number of commercially available, evidence-based therapeutic monoclonal antibodies continues to expand. In oncology, immune checkpoint inhibitors are particularly important, as a wide range of central and peripheral nervous system complications are described. In rheumatology, anti-TNF alpha drugs remain associated with demyelinating syndromes. The number of therapeutic monoclonal antibodies encountered in practice continues to grow, as does the number of described neurological complications. Recognition of a possible drug complication is key, as these are typically complex patients at risk of other causes of neurological injury. Identification of a complication of therapy often leads to intervention and a change in management.
Indexed as
Identifiers
28819716What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.